Form 4: BridgeBio Pharma Director Exercises Stock Options, Acquires Shares

Director Ali J. Satvat exercised stock options to acquire BridgeBio Pharma shares at various prices on December 30, 2024.

Summary

• On December 30, 2024, Ali J. Satvat, a director at BridgeBio Pharma, exercised stock options.
• The transactions involved the acquisition of 79,702 shares at $10.99, 39,851 shares at $16.68, and 39,851 shares at $26.21.
• These transactions resulted in a total of 159,404 shares being acquired by the director.
• The stock options were fully vested and exercisable as of January 26, 2021.

Sentiment

Score: 6

Explanation: The document is a routine filing of stock option exercises, which is neither particularly positive nor negative. It indicates a director's activity in the company's stock.

Positives

• The exercise of stock options by a director could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers who transact in their company's stock. It provides transparency into insider transactions.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The exercise of stock options is a common form of compensation for directors and executives in the biotech industry.
• The prices at which the options were exercised are specific to the terms of the options granted to the director.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it increases the number of shares outstanding.

Key Dates

Keywords

stock options, insider trading, share acquisition, director, BridgeBio Pharma, BBIO